Dosing and administration [1]
This page/content is for Great Britain healthcare professionals only.
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Dosing and administration
Please refer to the Pluvicto SmPC for full information about dosing and administration.1
Pluvicto is a ready-to-use solution. Be aware that treatment with Pluvicto contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk for cancer.1
Great Britain posology: Pluvicto is administered every 6 weeks (± 1 week) for a total of 6 doses.1
One dose of Pluvicto contains 7.4 GBq (200 mCi) – at time of use.*1
There are 3 ways to administer Pluvicto:1
- As an injection using a disposable syringe fitted with a syringe shield (with or without a syringe pump)
- As an infusion using the gravity method (with or without an infusion pump)
- As an infusion using the vial (using a peristaltic infusion pump)
For more information on the 3 administration methods, please watch the videos below.